- Home
- DFDV vs ANNX Comparison
DFDV vs ANNX Comparison
Compare DFDV & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFDV
- ANNX
- Stock Information
- Founded
- DFDV 2018
- ANNX 2011
- Country
- DFDV United States
- ANNX United States
- Employees
- DFDV N/A
- ANNX N/A
- Industry
- DFDV Finance: Consumer Services
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- DFDV Finance
- ANNX Health Care
- Exchange
- DFDV Nasdaq
- ANNX Nasdaq
- Market Cap
- DFDV 330.2M
- ANNX 334.1M
- IPO Year
- DFDV N/A
- ANNX 2020
- Fundamental
- Price
- DFDV $12.30
- ANNX $3.19
- Analyst Decision
- DFDV Buy
- ANNX Strong Buy
- Analyst Count
- DFDV 1
- ANNX 4
- Target Price
- DFDV $45.00
- ANNX $13.00
- AVG Volume (30 Days)
- DFDV 1.8M
- ANNX 1.8M
- Earning Date
- DFDV 11-12-2025
- ANNX 11-13-2025
- Dividend Yield
- DFDV N/A
- ANNX N/A
- EPS Growth
- DFDV N/A
- ANNX N/A
- EPS
- DFDV 1.17
- ANNX N/A
- Revenue
- DFDV $3,520,660.00
- ANNX N/A
- Revenue This Year
- DFDV $312.92
- ANNX N/A
- Revenue Next Year
- DFDV $141.18
- ANNX N/A
- P/E Ratio
- DFDV $10.49
- ANNX N/A
- Revenue Growth
- DFDV 97.13
- ANNX N/A
- 52 Week Low
- DFDV $0.44
- ANNX $1.29
- 52 Week High
- DFDV $48.98
- ANNX $7.63
- Technical
- Relative Strength Index (RSI)
- DFDV 36.47
- ANNX 54.06
- Support Level
- DFDV $13.75
- ANNX $2.89
- Resistance Level
- DFDV $15.10
- ANNX $3.60
- Average True Range (ATR)
- DFDV 1.20
- ANNX 0.23
- MACD
- DFDV -0.19
- ANNX -0.00
- Stochastic Oscillator
- DFDV 2.76
- ANNX 44.22
About DFDV DeFi Development Corp. Common Stock
DeFi Development Corp is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions as well as value-add services to multifamily and commercial property professionals.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.